Adagrasib-induced photodistributed hyperpigmentation: Two case reports and pathogenetic hypothesis - 21/05/25
Doi : 10.1016/j.therap.2024.12.014
Julien Lebled a, Jean-Paul Claudel b, Marie-Sarah Agier b, Laurent Plantier c, Bérenger Largeau a, Annie-Pierre Jonville-Bera a, ⁎ 
a Department of Pharmacosurveillance, Pharmacovigilance Regional Center of Centre Val-de-Loire, University Hospital of Tours, 37000 Tours, France
b Department of Dermatology, University Hospital of Tours, 37000 Tours, France
c Department of Pneumology, University Hospital of Tours, 37000 Tours, France
⁎Corresponding author.
Keywords : Adagrasib, Skin hyperpigmentation, Targeted therapy, Protein kinase inhibitor, Cutaneous adverse drug reaction
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| ☆ | The first case was notified to the Regional Pharmacovigilance Centre Val-de-Loire on July 16th 2024 under the number No. TS20240905 and the second case on September 12th 2024 under the number No. TS20241018. |
© 2025
Société française de pharmacologie et de thérapeutique. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 80 - N° 3
P. 333-336 - maggio 2025 Ritorno al numero
Articolo precedente
- A biological pharmacology network to secure the risk of drug–drug interaction with nirmatrelvir/ritonavir
- Florian Lemaitre, Lidvine Boland, Camille Tron, Matthieu Grégoire, Véronique Lelong-Boulouard, Peggy Gandia, Françoise Goirand, Nicolas Gambier, Christelle Boglione-Kerrien, Bénédicte Franck, Sébastien Lalanne, Arnaud Devresse, Sebastien Briol, Vincent Haufroid, Marie-Clémence Verdier, SFPT Therapeutic Drug Monitoring, Treatment Personalization group (STP-PT) of the French Society of Pharmacology, Therapeutics (SFPT)
- Dapagliflozin-induced leukocytoclastic vasculitis
- Dhouha Sahnoun, Houda Ghardallou, Myriam Agrebi, Mohamed Ben Rejeb, Najet Ghariani, Badreddine Sriha, Mohamed Denguezli, Chaker Ben Salem
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?